

Cytology and HPV Testing: Market Research Report

<https://marketpublishers.com/r/C2712655FDBEN.html>

Date: June 2012

Pages: 432

Price: US\$ 3,950.00 (Single User License)

ID: C2712655FDBEN

Abstracts

This report analyzes the worldwide markets for Cytology and HPV Testing in US\$ Million.

The report provides separate comprehensive analytics for the US, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2018.

The report profiles 43 companies including many key and niche players such as Abbott Molecular, Inc., BD Diagnostics-TriPath, CytoCore®, Inc., DaAn Gene Co., Ltd., Gen-Probe, Inc., Hologic, Inc., Third Wave Technologies, Inc., Merck & Co., Inc., QIAGEN NV, Qiagen North American Holdings, Inc., Roche Diagnostics, Ventana Medical Systems, Inc., and Roche mtm Laboratories AG.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Cytology and HPV Testing Market – Quick Facts
HPV Testing: A Prelude
Developing World Gears Up for HPV Vaccine

Table 1. World Age-Standardized Cervical Cancer Incidence Rates (2011): Breakdown by Region (includes corresponding Graph/Chart)

Table 2. Global Cervical Cancer Mortality Rates (2011): Breakdown by Region (includes corresponding Graph/Chart)

Current and Future Analysis
Cervical Cytology Screening: An Abstract
A Snapshot of Global Market Opportunity

Table 3. Number of New Cervical Cancer Cases in the World by Region and Age Group (2010) (includes corresponding Graph/Chart)

Table 4. Global HPV Testing Market (2011): Regional Breakup by Number of Tests and Penetration Rate

Challenges Faced by HPV Testing Market
Select Side Effects of HPV Vaccines
Legislative & Regulatory Environment Worldwide

Capitulation of Cervical Cancer Screening Guidelines (2009-2012)
HPV Test to be a Part of the New Cervical Cancer Screening Guidelines in the US
US Government Proposes Administration of HPV Vaccine for Males
Frequent Pap and HPV Test Recommendations for Cervical Cancer Screening in the US
US Cytology Screening Guidelines Support Co-testing of Cytology with HPV
Stringent NHS Guidelines for Cytology Laboratories
NCSP to Screen Women in New Zealand for Cervical Cancer
Reimbursement Scenario
Effect of HPV Vaccination on HPV Testing
Gardasil®
Cervarix®
HPV Vaccine Implementation Scenario
Global HPV Immunization Schedule and Population Coverage by Country
Select Market Overview
The United States
Canada
France
The United Kingdom
Australia
Mexico
Kenya

2.KEY TRENDS AND RESEARCH FINDINGS

Novel Technological Innovations to Enhance Accuracy of Screening Procedures
Regular HPV Screening Enhances Treatment and Survival Options
Co-testing of Pap Cytology and HPV for Enhanced Determination of Cervical Cancer Risk
Inhalable Cervical Cancer Vaccines to Grow in Popularity
Gardasil - A Biohazard? The Controversy Continues
Side-effects of Gardasil More Apparent Among Preteens
Increase in Instances of HPV-Linked Oral Cancer – A Cause of Deep Concern
New Research Findings Indicate Two Vaccination Doses Equal Three
HPV Vaccine Proves Beneficial in Prevention of Genital Warts in Men
Men Found to be More Susceptible to Oral HPV Infections

3.OVERVIEW OF CYTOLOGY AND HPV TESTING

What is HPV?

Types of HPV

Commonly Known Diseases and Related HPV Test Types

Common Types of HPV Diseases

Causes of Infection

Cervical Cancer and HPV

HPV and Other Cancers

Techniques for Detecting HPV

Signal-Amplified Nucleic Acid Assays

Target-Amplified HPV Assays

What is HPV Testing?

Test of HPV in Men

Test of HPV in Women

HPV Test Results

Positive HPV Test

Negative HPV Test

Limitations of HPV Testing

Advantages of HPV Testing

Cervical Cytology Observation/Screening

Pap Smear Screening

Requirements for Pap Smear Test

Advantages of Pap smear Test

Limitations of Cytologic Screening

HPV Testing vs. Cytology Testing

Future of HPV Testing

4.COMMERCIALLY AVAILABLE HPV TESTS

Digene HPV Test

CareHPV Test

Hybrid Capture-II Test

5.PRODUCT/SERVICE INTRODUCTIONS

Biodis to Launch Citofem® Cervical Cancer Screening Test

QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System in Europe

OncoHealth to Launch Protein-based Assay for HPV Testing

Independent Histopathology Services Launches Roche cobas 4800 System

Sensovation Introduces FLAIR Compact Fluorescent Array Imaging Reader
mtm Laboratories Unveils CINtec® PLUS Advanced Cervical Cancer Screening Product
Hoffmann-La Roche Launches cobas 4800 System
Roche Diagnostics Canada Launches cobas® 4800 Clinical Laboratory System
Histopathology & Specialty Laboratory Launches HPV Testing Range
AcroMetrix Introduces OptiQual® HPV Genotype Panel
SeraCare Life Sciences Introduces SeraCare HPV Genotype Performance Panel
Abbott Molecular Introduces PCR-Based Real-Time Diagnostic Test for HPV

6.ACCREDITATIONS/APPROVALS/ CERTIFICATIONS

FDA Grants Approval for Gen-Probe's PANTHER® System
Gen-Probe Receives FDA Approval for APTIMA® HPV Assay
Roche Receives FDA Approval for cobas HPV Test
mtm Laboratories Plans FDA Filings for Cervical Disease Tests
Merck Obtains FDA Approval for GARDASIL
QIAGEN Obtains CE Mark for careHPV Test
Hologic Receives Approval from FDA for Two HPV Tests

7.RECENT INDUSTRY ACTIVITY

Hologic Inks Definitive Agreement to Acquire Gen-Probe
Bio-Reference Laboratories Acquires Stake in InCellDx
QIAGEN Inks Co-Marketing Agreement with KingMed Diagnostics
Roche Signs Agreement with Unilabs-IHS to Expand Access to HPV Testing in UK
Roche Takes Over mtm Laboratories
Roche Inks Contract with Karolinska University Hospital for Cervical Cancer Screening
QIAGEN Establishes QIAGEN India
QIAGEN Signs Agreement with Abbott Laboratories
CytoCore Signs Agreement with Guangdong Prosper Channel Medicine Company
Life Technologies to Take Over AcroMetrix
Roche Molecular Systems Enters Into Research Collaboration with DKFZ
QIAGEN to Donate HPV DNA Test to Cancer Hospital in India
Xenomics Changes Name to TrovaGene
mtm Laboratories Inks Agreement with MetaSystems
CytoCore® and Amsino International Ink Agreement
Merck Collaborates with QIAGEN for Access to HPV DNA Testing
CytoCore® Inks Agreement with Synermed Select Partners
Xenomics Files Patent for New HPV Detection Test

8.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Molecular, Inc. (US)
BD Diagnostics-TriPath (US)
CytoCore®, Inc. (US)
DaAn Gene Co., Ltd. (China)
Gen-Probe, Inc. (US)
Hologic, Inc. (US)
Third Wave Technologies, Inc. (US)
Merck & Co., Inc. (US)
QIAGEN NV (The Netherlands)
Qiagen North American Holdings, Inc. (US)
Roche Diagnostics (Switzerland)
Ventana Medical Systems, Inc. (US)
Roche mtm Laboratories AG (Germany)

9.GLOBAL MARKET PERSPECTIVE

Table 5. World Recent Past, Current and Future Analysis for HPV Testing by Geographic Region/ Country – US, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

Table 6. World 10-Year Perspective for HPV Testing by Geographic Region/Country – Percentage Breakdown of Dollar Revenues for US, Europe, and Rest of World Markets for Years 2009, 2012 and 2018 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. Market Analysis
Current and Future Analysis
Key Statistics
Market Overview

Table 7. Prevalence of HPV in the US by Age (includes corresponding Graph/Chart)

Pap and HPV Test Strongly Advised for Cervical Cancer in the US

HPV Vaccine Implementation

Reimbursement of Screening Procedures

Regulatory Scenario

Overview of Cervical Cancer Screening Guidelines (2009-2012)

HPV Test to be a Part of the New Cervical Cancer Screening Guidelines in the US

US Government Proposes Administration of HPV Vaccine for Males

Frequent Pap and HPV Test Recommendations for Cervical Cancer Screening in the US

Cervical Cytology Screening Guidelines

NHS Guidelines for Cytology Laboratories

HPV Vaccine Implementation in the US States

HPV Vaccines Legislations Passed by Individual US States (2011-2012)

Product/Service Launches

Recent Industry Activity

Accreditations/Approvals/Certifications

Key Players

B. Market Analytics

Table 8. US Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)**2.EUROPE**

A. Market Analysis

Current and Future Analysis

HPV Testing and Cervical Cancer Incidence Rates in Europe

Table 9. European HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)

HPV – The Preferred Primary Screening for Cervical Cancer in Europe

B. Market Analytics

Table 10. European Recent Past, Current and Future Analysis for HPV Testing by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

Table 11. European 10-Year Perspective for HPV Testing by Geographic Region/Country – Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2012 and 2018 (includes corresponding Graph/Chart)

2A.FRANCE

A. Market Analysis
Current and Future Analysis
HPV Vaccine Implementation
B. Market Analytics

Table 12. French Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2B.GERMANY

A. Market Analysis
Current and Future Analysis
Product/Service Introductions
Accreditations/Approvals/Certifications
Key Player
B. Market Analytics

Table 13. German Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2C.ITALY

- A. Market Analysis
- Current and Future Analysis
- B. Market Analytics

Table 14. Italian Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2D.THE UNITED KINGDOM

- A. Market Analysis
- Current and Future Analysis
- Market Overview
- HPV Vaccine Implementation
- Recent Industry Activity
- Product/Service Introduction
- B. Market Analytics

Table 15. UK Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2E.REST OF EUROPE

- A. Market Analysis
- Current and Future Analysis
- Recent Industry Activity
- Product/Service Introductions
- Accreditations/Approvals/Certifications
- Key Players
- B. Market Analytics

Table 16. Rest of Europe Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3.REST OF WORLD

A. Market Analysis

Current and Future Analysis

Focus on Select Markets

Canada

Asia-Pacific

Table 17. Asian HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)

India

Table 18. HPV in India: Breakdown of Type- Distribution and HPV Prevalence (includes corresponding Graph/Chart)

Cervical Cancer Screening in India - Still a Long Way to Go

Australia

New Zealand

Latin America

Table 19. Latin America HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)

Mexico

Africa

Table 20. African HPV Testing Market (2011): Breakdown by % of Women Tested; HPV Prevalence Rate and Cervical Cancer Mortality Rates (includes corresponding Graph/Chart)

Recent Industry Activity

Product/Service Introductions

Key Player

B. Market Analytics

Table 21. Rest of World Recent Past, Current and Future Analysis for HPV Testing Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 43 (including Divisions/Subsidiaries - 56)

The United States (23)

Canada (2)

Europe (20)

- France (1)

- Germany (6)

- The United Kingdom (3)

- Italy (2)

- Spain (1)

- Rest of Europe (7)

Asia-Pacific (Excluding Japan) (10)

Middle East (1)

I would like to order

Product name: Cytology and HPV Testing: Market Research Report

Product link: <https://marketpublishers.com/r/C2712655FDBEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2712655FDBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970